LYMPHOID NEOPLASIA Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas
نویسندگان
چکیده
Thomas E. Witzig,1 Hui Tang,2 Ivana N. M. Micallef,1 Stephen M. Ansell,1 Brian K. Link,3 David J. Inwards,1 Luis F. Porrata,1 Patrick B. Johnston,1 Joseph P. Colgan,1 Svetomir N. Markovic,1 Grzegorz S. Nowakowski,1 Carrie A. Thompson,1 Cristine Allmer,2 Matthew J. Maurer,2 Mamta Gupta,1 George Weiner,3 Ray Hohl,3 Paul J. Kurtin,4 Husheng Ding,5 David Loegering,5 Paula Schneider,5 Kevin Peterson,5 Thomas M. Habermann,1 and Scott H. Kaufmann1,5
منابع مشابه
Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib was conducted in 93 adult patients with relapsed or refractory lymphoma. Patients received tipifarnib 300 mg twice daily on days 1-21 of each 28-day cycle. The median number of prior therapies was 5 (range, 1-17). For the aggressive B-cell, indolent B-cell, and T-cell and Hodgkin lymphoma (HL/T) groups, the response rates were...
متن کاملIdentification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia.
PURPOSE Microarray technology was used to identify gene expression markers that predict response to the orally available farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in acute myelogenous leukemia (AML). EXPERIMENTAL DESIGN Gene expression profiles from 58 bone marrow samples from a cohort of relapsed and refractory AML patients were analyzed on the Affymetrix U133A gene chip ...
متن کاملTipifarnib in the treatment of acute myeloid leukemia
Farnesyltransferase inhibitors (FTIs) are a new class of biologically active anticancer drugs. The exact anti-tumorigenic mechanism is currently unknown. FTIs inhibit farnesylation of a wide range of target proteins. In preclinical models, tipifarnib (R115777, Zarnestra(R)), a non-peptidomimetic competitive FTI, showed great potency against leukemic cells. Although it has recently demonstrated ...
متن کاملFarnesyltransferase inhibitor tipifarnib (ZarnestraTM, R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells. Short tile for running head: tipifarnib in polycythemia vera
Polycythemia vera (PV) is an acquired myeloproliferative disorder with primary expansion of the red cell mass leading to an increased risk of thrombosis and less frequently to myelofibrosis and secondary acute leukemia. Standard therapies include cytoreduction with either phlebotomy and chemotherapeutic agents and antithrombotic drugs. Because long term exposure to cytotoxic chemotherapy may in...
متن کاملA phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia.
This phase 2 study evaluated the efficacy and safety of the oral farnesyltransferase inhibitor tipifarnib in adults with refractory or relapsed acute myeloid leukemia (AML). Patients (n=252) received tipifarnib 600 mg twice a day for 21 days in 28-day cycles. Median age was 62 years; 99 (39%) patients were 65 years or older. Eleven (4%) of 252 patients achieved complete remission (CR) or comple...
متن کامل